No Data
No Data
Harrow Health 2024 Earnings Preview
Earnings Outlook For Harrow
Express News | Harrow Inc: Vevye to Be Included in Key Formularies From Jan 2025
Express News | Harrow : First Major Market Access Wins in 2025 Medicare Part D Prescription Drug Program
Harrow Announces Market Access Wins for VEVYE
Lake Street Maintains Harrow(HROW.US) With Buy Rating, Maintains Target Price $55
loading...
loading...